- Home
- VVR vs LXRX Comparison
VVR vs LXRX Comparison
Compare VVR & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVR | LXRX |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.3M | 465.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | VVR | LXRX |
|---|---|---|
| Price | $3.29 | $1.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 692.2K | ★ 1.7M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $3.55 | $0.28 |
| 52 Week High | $4.38 | $1.66 |
Technical Indicators
Market Signals| Indicator | VVR | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 68.63 |
| Support Level | $3.28 | $1.11 |
| Resistance Level | $3.31 | $1.23 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 64.29 | 97.86 |
Price Performance
Historical ComparisonAbout VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.